These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28329208)

  • 21. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis.
    Hyle EP; Jani IV; Lehe J; Su AE; Wood R; Quevedo J; Losina E; Bassett IV; Pei PP; Paltiel AD; Resch S; Freedberg KA; Peter T; Walensky RP
    PLoS Med; 2014 Sep; 11(9):e1001725. PubMed ID: 25225800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the front line of HIV virological monitoring: barriers and facilitators from a provider perspective in resource-limited settings.
    Rutstein SE; Golin CE; Wheeler SB; Kamwendo D; Hosseinipour MC; Weinberger M; Miller WC; Biddle AK; Soko A; Mkandawire M; Mwenda R; Sarr A; Gupta S; Mataya R
    AIDS Care; 2016; 28(1):1-10. PubMed ID: 26278724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting.
    van Zyl GU; Preiser W; Potschka S; Lundershausen AT; Haubrich R; Smith D
    Clin Infect Dis; 2011 Jan; 52(2):264-70. PubMed ID: 21288854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
    Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
    AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries.
    Tierrablanca LE; Ochalek J; Ford D; Babiker A; Gibb D; Butler K; Turkova A; Griffin S; Revill P;
    Medicine (Baltimore); 2018 Feb; 97(5):e9698. PubMed ID: 29384848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.
    ; Keiser O; Tweya H; Boulle A; Braitstein P; Schecter M; Brinkhof MW; Dabis F; Tuboi S; Sprinz E; Pujades-Rodriguez M; Calmy A; Kumarasamy N; Nash D; Jahn A; MacPhail P; Lüthy R; Wood R; Egger M
    AIDS; 2009 Sep; 23(14):1867-74. PubMed ID: 19531928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
    Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
    N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-financing for viral load monitoring during the course of antiretroviral therapy among patients with HIV/AIDS in Vietnam: A contingent valuation survey.
    Nguyen QL; Nguyen LH; Tran BX; Phan HT; Le HT; Nguyen HD; Tran TD; Do CD; Nguyen CM; Thuc VT; Latkin C; Zhang MW; Ho RC
    PLoS One; 2017; 12(2):e0172050. PubMed ID: 28199405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of disease stage on direct medical costs of HIV management: a review of the international literature.
    Levy A; Johnston K; Annemans L; Tramarin A; Montaner J
    Pharmacoeconomics; 2010; 28 Suppl 1():35-47. PubMed ID: 21182342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.
    Vijayaraghavan A; Efrusy MB; Mazonson PD; Ebrahim O; Sanne IM; Santas CC
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):91-100. PubMed ID: 17621241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives?
    Braithwaite RS; Nucifora KA; Yiannoutsos CT; Musick B; Kimaiyo S; Diero L; Bacon MC; Wools-Kaloustian K
    J Int AIDS Soc; 2011 Jul; 14():38. PubMed ID: 21801434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Analysis of Early vs Late Diagnosis of HIV-Infected Patients in South Carolina.
    Rampaul M; Edun B; Gaskin M; Albrecht H; Weissman S
    South Med J; 2018 Jun; 111(6):355-358. PubMed ID: 29863227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.
    Kahn JG; Marseille E; Moore D; Bunnell R; Were W; Degerman R; Tappero JW; Ekwaru P; Kaharuza F; Mermin J
    BMJ; 2011 Nov; 343():d6884. PubMed ID: 22074713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China.
    Zang X; Tang H; Min JE; Gu D; Montaner JS; Wu Z; Nosyk B
    PLoS One; 2016; 11(11):e0167308. PubMed ID: 27893864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.